🟢 Opus Genetics is trading 7.33% up in after-hours trading after positive BIRD-1 Cohort 1 results

Opus Genetics is trading 7.33% up at $6.15 in after-hours trading after reporting positive low-dose Cohort 1 results from its Phase 1/2 BIRD-1 trial.

• All five showed clinically meaningful improvement in at least one visual-function measure; four showed structural improvements.
• No serious safety issues were reported; potential Phase 3 dosing was discussed for 2027.
• Regular-session close: $5.73, after a 32.03% gain on September 9, 2026; the move followed the clinical-data announcement, not broader market strength.